Inequalities in enrollment of women and racial minorities in trials testing uric acid lowering drugs

被引:20
作者
Fogacci, Federica [1 ,2 ]
Borghi, Claudio [1 ,2 ]
Di Micoli, Antonio [2 ]
Degli Esposti, Daniela [2 ]
Cicero, Arrigo F. G. [1 ,2 ]
机构
[1] Alma Mater Studiorum Univ Bologna, Med & Surg Sci Dept, Hypertens & Cardiovasc Risk Factors Res Ctr, Bologna, Italy
[2] IRCCS Azienda Osped Univ Bologna, Bologna, Italy
关键词
Uric acid lowering drugs; Sex; Minorities; Clinical trials; XANTHINE-OXIDASE INHIBITOR; MOLECULAR ENTITY DRUGS; DOUBLE-BLIND; CLINICAL-TRIALS; SERUM URATE; INADEQUATE RESPONSE; GOUT PATIENTS; PHASE-III; FEBUXOSTAT; PLACEBO;
D O I
10.1016/j.numecd.2021.09.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: We investigated sex and racial inequalities in clinical trials testing serum uric acid (SUA) lowering drugs and analyzed the temporal trends of participation among the pre specified demographic groups. Data were collected from publications of clinical trials testing SUA-lowering drugs. Linear regression analysis was performed to assess the relation between drug approval year and proportion of women and minorities enrolled in clinical studies. Data synthesis: The mean percentage enrollment of women in clinical trials significantly decreased over the time (r =-0.43, P-value = 0.02). Moreover, there was a statistically significant difference in mean percentage enrollment of women among trials testing different SUAlowering drugs, with the highest representation in rasburicase (71.1%) and the lowest representation of women in dotinurad (0.8%). Over the time, also the mean percentage enrollment of racial minorities decreased, passing from 8.7% to 2.2% in a 10-year period. Women were proportionally underrepresented compared with their share of the population with asymptomatic hyperuricemia, overall (participation-to-prevalence ratio (PPR) = 0.34), in trials testing xanthine oxiase inhibitors (PPR = 0.38) and uricosurics (PPR = 0.29), and in trials with febuxostat, allopurinol, pegloticase, halofenate/arhalofenate, verinurad, lesinurad and dotinurad. Women were proportionally underreppresented also compared with their share of the population with gout, overall (PPR = 0.69) and in trials testing XOIs (PPR = 0.69), uricosurics (PPR = 0.68), and all SUA-lowering drugs excepted for rasburicase, pegloticase and topiroxostat. Conclusions: Our analysis shows that women and racial and ethnical minorities are underrepresented in controlled clinical trials testing SUA-lowering drugs, with similar pattern across drug classes. (c) 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:3305 / 3313
页数:9
相关论文
共 49 条
[1]  
[Anonymous], 1993, FED REGISTER
[2]  
[Anonymous], GBD COMP IHME VIZ HU
[3]   Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase [J].
Becker, Michael A. ;
Schumacher, H. Ralph, Jr. ;
Wortmann, Robert L. ;
MacDonald, Patricia A. ;
Palo, William A. ;
Eustace, Denise ;
Vernillet, Laurent ;
Joseph-Ridge, Nancy .
ARTHRITIS AND RHEUMATISM, 2005, 52 (03) :916-923
[4]   Uric acid and risk of myocardial infarction. A dynamic duo [J].
Borghi, Claudio ;
Bentivenga, Crescenzio ;
Cosentino, Eugenio R. .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 320 :23-24
[5]   Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella Heart Study [J].
Cicero, Arrigo Francesco Giuseppe ;
Fogacci, Federica ;
Giovannini, Marina ;
Grandi, Elisa ;
Rosticci, Martina ;
D'Addato, Sergio ;
Borghi, Claudio .
SCIENTIFIC REPORTS, 2018, 8
[6]   Effects of Febuxostat in Early Gout A Randomized, Double-Blind, Placebo-Controlled Study [J].
Dalbeth, Nicola ;
Saag, Kenneth G. ;
Palmer, William E. ;
Choi, Hyon K. ;
Hunt, Barbara ;
MacDonald, Patricia A. ;
Thienel, Ulrich ;
Gunawardhana, Lhanoo .
ARTHRITIS & RHEUMATOLOGY, 2017, 69 (12) :2386-2395
[7]   Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout Findings of a Phase III Clinical Trial [J].
Dalbeth, Nicola ;
Jones, Graeme ;
Terkeltaub, Robert ;
Khanna, Dinesh ;
Kopicko, Jeff ;
Bhakta, Nihar ;
Adler, Scott ;
Fung, Maple ;
Storgard, Chris ;
Baumgartner, Scott ;
Perez-Ruiz, Fernando .
ARTHRITIS & RHEUMATOLOGY, 2017, 69 (09) :1903-1913
[8]   Demographics of Clinical Trials Participants in Pivotal Clinical Trials for New Molecular Entity Drugs and Biologics Approved by FDA From 2010 to 2012 [J].
Eshera, Noha ;
Itana, Hawi ;
Zhang, Lei ;
Soon, Greg ;
Fadiran, Emmanuel O. .
AMERICAN JOURNAL OF THERAPEUTICS, 2015, 22 (06) :435-455
[9]  
Fadiran EO., 2015, Medicines for Women, P41, DOI DOI 10.1007/978-3-319-12406-3_2
[10]   Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials [J].
Fitz-Patrick, David ;
Roberson, Kent ;
Niwa, Kiyoshi ;
Fujimura, Takabumi ;
Mori, Koji ;
Hall, Jesse ;
Yan, Xiaohong ;
Shen, Zancong ;
Liu, Sha ;
Ito, Yasushi ;
Baumgartner, Scott .
MODERN RHEUMATOLOGY, 2019, 29 (06) :1042-1052